Funding source: KU Leuven
Award Identifier / Grant number: C1/018
Funding source: Horizon 2020 WIDENLIFE
Award Identifier / Grant number: 692065
Funding statement: The study was funded by the KU Leuven (C1/018) and the Horizon 2020 WIDENLIFE: 692065 to J.R.V.
We thank the team of the Centre for Human Genetics for the supplied data, as well as their efforts that helped write this article.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Employment or leadership: PV is a senior clinical investigator of the Research Foundation-Flanders (FWO).
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
1. Alldred SK, Takwoingi Y, Guo B, Pennant M, Deeks JJ, Neilson JP, et al. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down’s syndrome screening. Cochrane Database of Systematic Reviews 2017; 3: Article No.: CD012600. DOI: 10.1002/14651858.CD012600.Search in Google Scholar
2. Santorum M, Wright D, Syngelaki A, Karagioti N, Nicolaides KH. Accuracy of first-trimester combined test in screening for trisomies 21, 18 and 13. Ultrasound Obstet Gynecol 2017;49:714–20.Search in Google Scholar
3. Gil MM, Accurti V, Santacruz B, Plana MN, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obs Gynecol 2017;50:302–14.Search in Google Scholar
4. Taylor-Phillips S, Freeman K, Geppert J, Agbebiyi A, Uthman OA, Madan J, et al. Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: a systematic review and meta-analysis. BMJ Open 2016;6:e010002.Search in Google Scholar
5. Badeau M, Lindsay C, Blais J, Nshimyumukiza L, Takwoingi Y, Langlois S, et al. Genomics‐based non‐invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women. Cochrane Database of Systematic Reviews 2017;11: Article No.: CD011767. DOI: 10.1002/14651858.CD011767.pub2.Search in Google Scholar
6. Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open 2014;4:e005922.Search in Google Scholar
7. Bayindir B, Dehaspe L, Brison N, Brady P, Ardui S, Kammoun M, et al. Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. Eur J Hum Genet 2015;23:1286–93.Search in Google Scholar
8. Brison N, Neofytou M, Dehaspe L, Bayindir B, Van Den Bogaert K, Dardour L, et al. Predicting fetoplacental chromosomal mosaicism during non-invasive prenatal testing. Prenat Diagn 2018;38:258–66.Search in Google Scholar
9. Brison N, Van Den Bogaert K, Dehaspe L, van den Oever JME, Janssens K, Blaumeiser B, et al. Accuracy and clinical value of maternal incidental findings during noninvasive prenatal testing for fetal aneuploidies. Genet Med 2017;19:306–13.Search in Google Scholar
10. Gyselaers WJ, Vereecken AJ, Van Herck EJ, Straetmans DP, De Jonge ET, Ombelet WU, et al. Audit on nuchal translucency thickness measurements in Flanders, Belgium: a plea for methodological standardization. Ultrasound Obstet Gynecol 2004;24:511–5.Search in Google Scholar
©2019 Walter de Gruyter GmbH, Berlin/Boston